Strategies to Counteract Botulinum Neurotoxin A: Nature's Deadliest Biomolecule.
Level 5 - mechanism / opinion, no new human data
Narrative review and account of bench and preclinical drug discovery research without clinical data.
PubMed 31322847 · doi:10.1021/acs.accounts.9b00261
What was done
The authors reviewed nearly two decades of their laboratory's small-molecule drug discovery research against Botulinum neurotoxin serotype A (BoNT/A). The account covers identification and characterization of chemical leads via high-throughput screening and rational design, assay development in vitro and in vivo, structural biology insights, and mechanistic inhibition strategies including noncovalent, metal-binding, covalent, and exosite inhibitors.
What was found
No quantitative efficacy outcome numbers are reported in the abstract. The abstract notes that BoNT/A has an estimated human intravenous lethal dose (LD50) of 1-2 ng/kg, and antibody therapy is limited to a 12-24 hour window postexposure. No small-molecule BoNT/A inhibitors have reached clinical trials. Key translational challenges identified include toxin half-life in neurons spanning months to over one year compared to in vivo drug lifetimes, and poor concordance between in vitro, cellular, and in vivo assays.
Why it matters
BoNT/A is an extremely lethal Category A biothreat agent with no existing small-molecule antidotes capable of reversing intracellular intoxication. This account defines the primary chemical and pharmacodynamic obstacles preventing clinical translation and advocates focusing on covalent inhibitors.
Limits
This is a narrative account of preclinical and bench research from a single research group, containing no human clinical trials or systematic review data. The abstract provides no specific quantitative assay results or comparative statistical metrics.
Cited by
- contradicts Mercury is the second most potent toxin on Earth after plutonium.